COST-EFFECTIVENESS OF TREATMENT STRATEGIES INITIATED AT DIFFERENT STAGES OF LIVER FIBROSIS FOR JAPANESE PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1

被引：1
|
作者：
Suenaga, R. [1 ]
Suka, M. [2 ]
Hirao, T. [3 ]
Ikai, H. [4 ]
Hidaka, I [1 ]
Sakaida, I [1 ]
Ishida, H. [1 ]
机构：
[1] Yamaguchi Univ, Grad Sch Med, Ube, Yamaguchi, Japan
[2] Jikei Univ, Sch Med, Tokyo, Japan
[3] Kagawa Univ, Miki, Kagawa, Japan
[4] Yamaguchi Univ, Ube, Yamaguchi, Japan
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.3036
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PGI21
引用
收藏
页码：A635 / A635
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of a "treat-all" strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages
    Suenaga, Riichiro
    Suka, Machi
    Hirao, Tomohiro
    Hidaka, Isao
    Sakaida, Isao
    Ishida, Haku
    PLOS ONE, 2021, 16 (04):
  • [2] Cost-Effectiveness of Noninvasive Liver Fibrosis Tests for Treatment Decisions in Patients With Chronic Hepatitis C
    Tsochatzis, Emmanuel A.
    Crossan, Catriona
    Longworth, Louise
    Gurusamy, Kurinchi
    Rodriguez-Peralvarez, Manolo
    Mantzoukis, Konstantinos
    O'Brien, Julia
    Thalassinos, Evangelos
    Papastergiou, Vassilios
    Noel-Storr, Anna
    Davidson, Brian
    Burroughs, Andrew K.
    HEPATOLOGY, 2014, 60 (03) : 832 - 843
  • [3] Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease
    Leidner, Andrew J.
    Chesson, Harrell W.
    Xu, Fujie
    Ward, John W.
    Spradling, Philip R.
    Holmberg, Scott D.
    HEPATOLOGY, 2015, 61 (06) : 1860 - 1869
  • [4] COST-EFFECTIVENESS OF BOCEPREVIR IN THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 1 IN SWEDEN
    Chhatwal, J.
    Lundberg, J.
    Ferrante, S.
    El Khourhy, A. C.
    Oksanen, A.
    Elbasha, E. H.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S386 - S387
  • [5] THE COST-EFFECTIVENESS OF HEPATITIS C TREATMENTS IN TREATMENT NAIVE GENOTYPE 1 PATIENTS
    McGinnis, J. J.
    Hay, J. W.
    VALUE IN HEALTH, 2014, 17 (03) : A274 - A274
  • [6] COST-EFFECTIVENESS OF HEPATITIS C TREATMENT FOR LEBANESE PATIENTS IN EARLY STAGES OF LIVER DISEASE
    Nasser, S.
    Nader, Abi T.
    Mansour, H.
    VALUE IN HEALTH, 2017, 20 (05) : A78 - A78
  • [7] Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C
    Camma, Calogero
    Petta, Salvatore
    Enea, Marco
    Bruno, Raffaele
    Bronte, Fabrizio
    Capursi, Vincenza
    Cicchetti, Americo
    Colombo, Giorgio L.
    Di Marco, Vito
    Gasbarrini, Antonio
    Craxi, Antonio
    HEPATOLOGY, 2012, 56 (03) : 850 - 860
  • [8] Cost-effectiveness analysis of sofosbuvir-simeprevir regimens for chronic hepatitis C genotype 1 patients with advanced fibrosis
    Mar, Javier
    Mar-Barrutia, Lorea
    Gimeno-Ballester, Vicente
    San Miguel, Ramon
    MEDICINA CLINICA, 2016, 146 (02): : 61 - 64
  • [9] Cost-effectiveness analysis of different protease inhibitors-based strategies in the treatment of naive patients with genotype 1 chronic hepatitis C (G1-CHC)
    Papatheodoridis, George V.
    Arzoumanidou, Daphne
    HEPATOLOGY, 2012, 56 : 1014A - 1014A
  • [10] Management of treatment-naive chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options
    Cortesi, P. A.
    Ciaccio, A.
    Rota, M.
    Lim, J. K.
    De Salvia, S.
    Okolicsanyi, S.
    Vinci, M.
    Belli, L. S.
    Mantovani, L. G.
    Strazzabosco, M.
    JOURNAL OF VIRAL HEPATITIS, 2015, 22 (02) : 175 - 183
12345